Fluorine F 18 DCFBC PET/CT in Imaging Patients with Prostate Cancer

Inclusion Criteria

• Platelet count > 50,000/mm^3
• Eastern Cooperative Oncology Group (ECOG) performance score of 0 to 2
• Ability to provide informed consent; all subjects must sign an informed consent form indicating their understanding of the investigational nature and risks of the study before any protocol-related studies are performed
• ARM I ONLY: For patients with presumed localized disease (any T, N0, M0), a multiparametric MRI (standard of care at the National Institutes of Health [NIH] Clinical Center) must be performed within 4 months of the 18F-DCFBC injection with findings suggestive for prostate cancer and a prostate lesion at least 6 mm or greater; must have histopathologic confirmation of prostate cancer prior to 18F-DCFBC imaging
• ARM II ONLY: For patients status post radiation therapy for prostate cancer, any PSA increase from post radiation therapy nadir OR
• ARM II ONLY: For patients status post prostatectomy, a PSA >= 0.2 ng/ml
• ARM II ONLY: Nonspecific or no evidence for disease on standard imaging modality
• ARM III ONLY: Patients must have identifiable metastatic disease on at least 1 clinically indicated imaging modality; if only soft tissue metastasis, one lesion must measure at least 6 mm or greater; patients must have confirmation of prostate cancer prior to 18F-DCFBC imaging * Note: a patient who is eligible for one arm, subsequently may cross-over into a different arm

Exclusion Criteria

• Subjects for whom participating would significantly delay the scheduled standard of care therapy
• Subjects with any coexisting medical or psychiatric condition that is likely to interfere with study procedures and/or results
• Subjects with severe claustrophobia unresponsive to oral anxiolytics
• Other medical conditions deemed by the principal investigator (or associates) to make the subject unsafe/ineligible for protocol procedures
• Subjects weighing > 350 lbs. (weight limit for scanner table), or unable to fit within the imaging gantry
• Serum creatinine > 2 times the upper limit of normal
• Total bilirubin > 2 times the upper limit of normal
• Liver transaminases (alanine aminotransferase [ALT], aspartate aminotransferase [AST]) greater than 3 times the upper limit of normal